The Cytel Blog: Perspectives on Enquiry & Evidence

   Francois Beckers, Global Head of Biostatistics & Epidemiology at Merck KGaA joined us at the East User Group Meeting..

On March 16th and 17th the 5th East User Group Meeting took place in London.  This very successful 2 days saw a variety..

Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods..

It is often necessary to pool safety data from late phase studies, in preparation for regulatory submission. Some of..

Our Client's Challenge: Can knowledge of the relationship between biomarkers and clinical endpoints help us to optimize..

If you’re in the practice of conducting early phase clinical trials, you’ve probably heard that modern trial designs..

When approaching a Phase 3 clinical trial, the need to ‘de-risk’ the massive investment often leads sponsors on a quest..

Seamless adaptive clinical trials have gained popularity for reducing the projected time it takes to complete the..

Last week the Cytel Blog discussed the benefits of using the Adaptive Maximizing Design [AM Design] for dose-finding..